Gastric cancer is the fifth most common cancer worldwide and its incidence is rising. Surgery is the only curative strategy and its association with perioperative chemotherapy is now standard treatment for most resectable tumors. Despite treatment advances, disease relapse is high, even in early stages, and continued improvement in curative treatment is imperative. With deeper knowledge of gastric cancer heterogeneity, molecular subtypes, and the tumor immune microenvironment, new standard treatment strategies may emerge in the near future. This paper provides a comprehensive review of the current treatment landscape in resectable gastric cancer and future perspectives for the next decade regarding new agents such as targeted therapies, immunotherapy, antibody–drug conjugates, and the combination of multiple treatment modalities.
胃癌是全球第五大常见癌症，其发病率正持续上升。手术是目前唯一可能根治的治疗手段，结合围手术期化疗已成为大多数可切除肿瘤的标准治疗方案。尽管治疗手段不断进步，但即使在早期阶段，疾病复发率仍然较高，因此持续改进根治性治疗方案至关重要。随着对胃癌异质性、分子亚型及肿瘤免疫微环境认识的深化，新的标准治疗策略有望在不久的将来出现。本文全面综述了当前可切除胃癌的治疗现状，并对未来十年靶向治疗、免疫治疗、抗体药物偶联物以及多种治疗模式联合应用等新型药物的发展前景进行了展望。
Perioperative Treatment in Gastric Cancer: A Fast-Changing Field
肿瘤(癌症)患者之家